Wells Fargo
NGNE icon

Wells Fargo’s Neurogene NGNE Stock Holding History

Wells Fargo’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298K Buy
9,471
+5,203
+122% +$143K ﹤0.01% 4947
2026
Q1 		$86K Sell
4,268
-6,769
-61% -$131K ﹤0.01% 5184
2025
Q4 		$227K Buy
11,037
+3,438
+45% +$85.6K ﹤0.01% 5000
2025
Q3 		$132K Buy
7,599
+1,232
+19% +$24.7K ﹤0.01% 5171
2025
Q2 		$95.2K Sell
6,367
-53
-0.8% -$832 ﹤0.01% 5221
2025
Q1 		$75.2K Buy
6,420
+976
+18% +$17K ﹤0.01% 5240
2024
Q4 		$124K Buy
5,444
+1,397
+35% +$52K ﹤0.01% 5075
2024
Q3 		$170K Buy
4,047
+30
+0.7% +$1.16K ﹤0.01% 4686
2024
Q2 		$146K Buy
4,017
+3,546
+753% +$125K ﹤0.01% 4711
2024
Q1 		$24K Buy
471
+57
+14% +$1.9K ﹤0.01% 5531
2023
Q4 		$8.02K Buy
414
+1
+0.2% +$14 ﹤0.01% 5885
2023
Q3 		$6.53K Buy
413
+1
+0.2% +$15 ﹤0.01% 5908
2023
Q2 		$6.84K Hold
412
– – ﹤0.01% 6012
2023
Q1 		$5.76K Buy
412
+1
+0.2% +$12 ﹤0.01% 6017
2022
Q4 		$4.19K Hold
411
– – ﹤0.01% 5824
2022
Q3 		$5K Hold
411
– – ﹤0.01% 5911
2022
Q2 		$8K Sell
411
-162
-28% -$3.95K ﹤0.01% 5844
2022
Q1 		$22K Sell
573
-661
-54% -$38.6K ﹤0.01% 5978
2021
Q4 		$118K Buy
1,234
+755
+158% +$92K ﹤0.01% 5546
2021
Q3 		$69K Sell
479
-120
-20% -$18.4K ﹤0.01% 5520
2021
Q2 		$110K Sell
599
-146
-20% -$32.3K ﹤0.01% 5271
2021
Q1 		$184K Sell
745
-1,798
-71% -$460K ﹤0.01% 5194
2020
Q4 		$717K Buy
2,543
+85
+3% +$20.8K ﹤0.01% 4265
2020
Q3 		$591K Sell
2,458
-359
-13% -$87K ﹤0.01% 4227
2020
Q2 		$936K Buy
2,817
+2,805
+23,375% +$731K ﹤0.01% 3864
2020
Q1 		$3K Buy
+12
New +$2.47K ﹤0.01% 5944
2018
Q2 		– Sell
-184
Closed -$52K – 6484
2018
Q1 		$52K Buy
+184
New +$50.8K ﹤0.01% 5554
2016
Q4 		– Sell
-38
Closed -$10K – 6380
2016
Q3 		$10K Buy
+38
New +$7.66K ﹤0.01% 5763

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Wells Fargo's NGNE Position: Q2 2026 in Review

Wells Fargo increased its Neurogene (NGNE) stake by 122% in Q2 2026, buying an estimated $143K and bringing the position to 9,471 shares worth $298K. The position accounts for ﹤0.01% of the portfolio, ranked #4947.

Wells Fargo first reported a position in NGNE in Q3 2016 and has held it in 28 quarters since. The position peaked at $936K in Q2 2020. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Wells Fargo held 9,471 shares of Neurogene worth $298K as of Q2 2026.
  • Wells Fargo bought 5,203 Neurogene shares in Q2 2026, an estimated $143K.
  • Neurogene made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4947 holding.
  • Wells Fargo first reported a position in Neurogene in Q3 2016 and has held it in 28 quarters since.
  • Wells Fargo's Neurogene position peaked at $936K in Q2 2020.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.